Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626044 | 1.00 | ADRB2 (0.67) | ADRB2CHRM3ERCC1ERCC4 | |
| SCHEMBL3619543 | 0.92 | ADRB2 (0.79) | ADRB2CHRM3 | |
| SCHEMBL3619539 | 0.92 | ADRB2 (0.79) | ADRB2CHRM3 | |
| SCHEMBL3623819 | 0.90 | ADRB2 (0.80) | ADRB2CHRM3 | |
| SCHEMBL5137151 | 0.90 | ADRB2 (0.55) | ADRB2 | |
| SCHEMBL3623815 | 0.90 | ADRB2 (0.80) | ADRB2CHRM3 | |
| SCHEMBL5137153 | 0.90 | ADRB2 (0.55) | ADRB2 | |
| SCHEMBL3623597 | 0.89 | ADRB2 (0.67) | ADRB2CHRM3 | |
| SCHEMBL3618195 | 0.89 | ADRB2 (0.67) | ADRB2CHRM3 | |
| SCHEMBL3618094 | 0.89 | ADRB2 (0.67) | ADRB2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730103-B1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LTD (GB) | 2010-05-26 | — | — | EP | claimed |
| JP-2007530524-A | — | — | 2007-11-01 | — | — | JP | claimed |
| EP-1730103-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| EP-1730103-B1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LTD (GB) | 2010-05-26 | — | — | EP | disclosed |
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | ADRB2 751/4885CHRM3 927/4885ERCC1 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.